TITLE:
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)

CONDITION:
Chronic Obstructive Pulmonary Disease

INTERVENTION:
Roflumilast

SUMMARY:

      The purpose of this study is to determine whether roflumilast is effective in the treatment
      of exacerbations in patients with chronic obstructive pulmonary disease (COPD).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 40 Years to N/A
Criteria:

        Main Inclusion Criteria:

          -  FEV1/FVC ratio (post-bronchodilator) 70%

          -  FEV1 (post-bronchodilator) 50% of predicted

          -  Current smoker or ex-smoker

          -  Clinically stable COPD indicated by no exacerbation and no change in COPD treatment
             of within 4 weeks prior to baseline

          -  Availability of chest x-ray dated a maximum of 6 months prior to study baseline or a
             willingness to have a chest x-ray performed at baseline

        Main Exclusion Criteria:

          -  COPD exacerbation indicated by a treatment with systemic glucocorticoids not stopped
             4 weeks prior to baseline

          -  Lower respiratory tract infection not resolved 4 weeks prior to baseline

          -  Diagnosis of asthma and/or other relevant lung disease

          -  Known alpha-1-antitrypsin deficiency

          -  Need for long-term oxygen therapy defined as 16 hours/day
      
